Collagen Solutions Share Discussion Threads

[pugugly] 21/2/2018 15:44

timbo - Thanks for link - Interesting case histories and product verification but no real guide to how will be driven forward BUT amybe price sentative and so not able to reveal.

[timbo003] 21/2/2018 14:16

There's a new interview with Jamal Rushdy on Proactive, I cannot access right now, but will look at it later:

[pugugly] 21/2/2018 10:47

Looks like the big seller is still with us depressing price - Any thought as to hwo many they still are looking to unload ?

[18bt] 21/2/2018 08:50

News this morning proves there is a product and a market. Needs the CE mark approval. Not clear whether submission or approval targeted for H2.

[lucicavi] 13/2/2018 13:47

not much cash left


BUST in 18 months or less

[thorne3] 06/2/2018 13:27

It's looking a bit like the latter at long last.

[pugugly] 05/2/2018 11:39

No published news but share price perking up - Anyone know if new broker's note published or mentioned in the weekend press or Mr Market waking up to potential ??

[melodrama] 20/12/2017 17:02

Thanks for your "opinion", interstellar

[interstellar] 20/12/2017 16:59

Once upon a time I was very keen on this stock- I went to investor briefings in London and listened to wild expectations from the then MD. Nothing has happened since- missed sales target after missed sales target. Lame excuses about why. The sad truth is too many senior managers getting fat and doing nothing useful to justify their fat salaries whilst the investors lose out. Irrelevent company announcements that add nothing. I have written this off and only the company and occasional AVDFN message alert kkeps it alive in my in-tray. Only the maggots making the skin move- love the metaphor but sadly it is the truth

[melodrama] 20/12/2017 16:56

Maybe its now in play

[melodrama] 20/12/2017 16:55

Mill buy, Mill sell, doubt the MM would take that on without a buyer, but who knows

[pugugly] 20/12/2017 16:50

So who is unloading Any thoughts Knowledge ?

- Looks like some 1% plus of shares dumped today -(however looks like some of the sells may have been buys by looking at the traded prices) OK a bit of a guess as trades do not seem to be cumulating correctly

- And how much further to fall - or to put it another way "how desperate is the seller to unload and how much pain are they prepared to suffer?"

Or is there any value left or is interstellar post 549 correct and this is a dead dog with only the maggots making the skin move !!!

[melodrama] 20/12/2017 15:41

Fortunately only a couple of small purchases at 3.2 for me recently, so I can take short term pain and give them "a chance" LOL. Here what you say. Lets see what gives in the coming months.

[interstellar] 20/12/2017 13:58

South Korean Medical companies are just about as flaky as they come. No financial details for a reason- beware. We have all lost shedloads on this stock it won't stop IMHO.

[tomboyb] 20/12/2017 13:17

Yep Melo - The seller seems to have sold in 2 batches at 3p -

250k and 500K -

That provided the mm's with stock -

Briefly reading through it does remind me of an early AMS -

AMS at 4pish now trading at £3.32 in 2003 to 20.17 -

Very much institutional based stock -

However will delve further on COS -

[colin12345678] 20/12/2017 12:29

cannot even get a quote for £250 to buy

[melodrama] 20/12/2017 12:19

That non-exec joining also encouraging. Unfort there is a pesky seller lurking, so he needs to clear before it can really move.

[colin12345678] 20/12/2017 12:18

Hard to buy

[tomboyb] 20/12/2017 12:13

Reminds me a bit of an early AMS -

Not fully researched here but a small punt of 50k -

[tomboyb] 20/12/2017 12:06

thanks melo -

[melodrama] 20/12/2017 12:04

Good news

First Partner Deal Agreed with South Korean Partner

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine applications including orthopaedics, dental, wounds, and cardiovascular, announces its first partnering deal for ChondroMimetic(R) with a South Korean partner, Insung Medical Co. Ltd. ("Insung Medical"). Financial terms have not been disclosed.

ChondroMimetic(R) is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee. The company is expecting results from an eight-year clinical extension study to be reported in Q1 2018.

Insung Medical, based in the Wonju Medical Industry Techno Valley near Seoul, was originally established in 1984 and focuses on manufacturing and sales of consumable surgical products to domestic and overseas markets. Insung's existing product range and sales provides access to multiple local markets in South Korea. Subject to approval, ChondroMimetic(R) will be commercialised by Insung Medical in collaboration with the existing Collagen Solutions commercial office in Seoul which will also provide technical and educational support.

Jamal Rushdy, CEO of Collagen Solutions, commented: "We are delighted to announce our first partnering deal with Insung Medical, providing early validation of the global commercial opportunity of ChondroMimetic(R). Insung Medical's enthusiasm for the opportunity to commercialise ChondroMimetic(R) in South Korea aligns with our strategy to launch the product to address the unmet need for a simple, cost-effective and long-term clinically effective treatment for cartilage defects."

Mr. In Keum Song, Chairman of Insung Medical added: "I am very delighted to partner with Collagen Solutions for its ChondroMimetic product line. I look forward to a long term positive business relationship with Collagen Solutions as we expand into new technologies".

Following the anticipated completion of the aforementioned extension study next quarter, Collagen Solutions and Insung Medical will collaborate to apply for approval by the Korean Ministry of Food And Drug Safety (MFDS) in parallel with Collagen Solutions' application for the CE Mark for European approval. Expected timing of such MFDS approval is not determined at this time.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

[jacobjohn7] 06/12/2017 21:47

an important nugget of info is also the permission to supply and trade by the Chinese government, that's a hurdle crossed to the biggest developing market in the world.

[jacobjohn7] 06/12/2017 21:41

as most who are invested know is that the customer list continues to grow the products in development continue to grow, there are some astute funds invested and continue to be so. The news which will come is the results of the long term scans and outcomes of 8 years if these are favourable (they were already at 6 month stage) then that will be the longest proven record for any comparable product on the market, then the CE mark reapproval will follow, this is just one product, and then they will step up the value chain. I continue to wait, and yes if youre not a day trader pecking little bits of profits or losses here and there then you do your calculations, find the right company and wait for the favourable times. dyor. all the best

[columbarius] 06/12/2017 12:21

The non-exec chairman invested at least £1m of his own cash as shown by six purchases since March 2015. His paper loss on these transactions is £400k so at least he is motivated to turn things around.